Medicinal marijuana: A comprehensive review

Journal of Psychoactive Drugs

Volumn 30, Issue 2, 1998, Pages 137-147

  Gurley, R Jan ^a   Aranow, Richard ^a   Katz, Mitchell ^a  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Cannabinoids; Cannabis; Clinical; Marijuana; Review

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; TETRAHYDROCANNABINOL;

ADDICTION; ASTHMA; CANCER CHEMOTHERAPY; DEPRESSION; DRUG DEPENDENCE; DRUG USE; EPILEPSY; GLAUCOMA; GYNECOMASTIA; HUMAN; INFECTION; LUNG INJURY; MENTAL DISEASE; MIGRAINE; NAUSEA; PANIC; REVIEW; VOMITING;

EID: 0031876116     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.1998.10399683     Document Type: Article

References (114)

1. Abboud, R. & Sanders, H. 1976. Effect of oral administration of delta-9-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Chest 70:480-5.
2. Abood, ME. & Martin, B.R. 1992. Neurobiology of marijuana abuse. Trends in Pharmacological Sciences 13 (5): 201-6.
3. Abood, M.E.; Sauss, C.; Fan, F.; Tilton, C.L.; Martin, B.R. 1993. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacology, Biochemistry and Behavior 46 (3): 575-9.
4. Abrahamov, A.; Abrahamov, A. & Mechoulam, R. 1995. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 56 (2324): 2097-102.
5. Aceto, M.D.; Scates, S.M.; Lowe, J.A. & Martin, B.R. 1996. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. Journal of Pharmacology and Experimental Therapeutics 278 (3): 1290-5.
6. Aceto, M.D.; Scates, S.M.; Lowe, J.A. & Martin, B.R. 1995. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. European Journal ofPharmacology 282 (1-3): R1-2.
7. Adams, I B. & Martin, B.R. 1996. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 91 (II): 1585-614. [Good overview of cannabinoids, their pharmacology, and the newer, isolated compounds]
8. Adams, M.D.; Earnhardt, J.T.; Dewey, W.L. & Harris, L.S. 1976. Vasoconstrictor actions of delta-8- and delta-9-tetra-hydrocannabinol in the rat. Journal of Pharmacology and Experimental Therapeutics 196 (3): 649-56.
9. Allebeck, P.; Adamsson, C. & Engstrom, A. 1993. Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica 88:21-24.
10. Ascher, M.; Sheppard, H.; Winkelstein, W. & Vittinghoff, E. 1993. Does drug use cause AIDS? Nature 362: 103-4
11. Bar-Joseph, A.; Berkovitch, Y.; Adamchik, J. & Biegon, A. 1994. Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Molecular and Chemical Neuropathology 23 (2-3): 125-35.
12. Bass, R.; Engelhard, D.; Trembovler, V. & Shohami, E. 1996. A novel non psychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. Journal of Infectious Diseases 173 (3): 735-8.
13. Belayev, L.; Busto, R.; Zhao, W. & Ginsberg, M.D. 1995. HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke 26 (12): 2313-20.
14. Bouaboula, M.; Rinaldi, M.; Carayon, P; et al. 1993. Cannabinoid-receptor expression in human leukocytes. European Journal of Biochemistry 214 (1): 173-80.
15. Bruera, E. 1992. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 49:35-42.
16. Cabral, G.A. & Vasquez, R. 1992. Delta 9-tetrahydrocannabinol suppresses macrophage extrinsic antiherpesvirus activity. Proceedings of the Society for Experimental Biology and Medicine 199 (2): 255-63.
17. Cabral, G.A.; Toney, D.M.; Fischer-Stenger, K.; Harrison, M.P. & Marciano-Cabral, F. 1995. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sciences 56 (23-24): 2065-72.
18. Caiaffa, W.; Vlahov, D.; Graham, N.; et al. 1994. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. American Journal of Respiratory and Critical Care Medicine 150:1493-8.
19. Cat, L. & Coleman, R. 1994. DIAS Rounds: Treatment for HIV wasting syndrome. Annals of Pharmacotherapy 28:505-7.
20. Cates, W. & Warren, J. 1975. Hepatitis B in Nuremberg, Germany. Journal of the American Medical Association 234 (9): 930-4.
21. Chan, H.; Correia, J. & MacLeod, S. 1987. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial. Pediatrics 79 (6): 946-52.
22. Chang, A.; Shiling, D.; Stillman, R; et al. 1979. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. Annals of Internal Medicine 91:819-24.
23. Chapman, L.; Chapman, J.; Kwapil, T.; Eckblad, M. & Zinser, M. 1994. Putatively psychosis prone individuals ten years on. Journal of Abnormal Psychology 103:171-83.
24. Conant, M.; Roy, D.; Shepard, K. & Plasse, T. 1991. Dronabinol enhances appetite and controls weight loss in HIV patients. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. San Francisco:University of California.
25. Condie, R.; Herring, A.; Koh, W.S.; Lee, M. & Kaminski, N.E. 1996. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.1L-2. Journal of Biological Chemistry 271 (22): 13175-83.
26. Consroe, P.; Sandyk, R. & Snider, S. 1986. Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience 30:277-82.
27. Consroe, P.; Wood, G. & Buchsbaum, H. 1975. Anticonvulsant nature of marijuana smoking. Journal of the American Medical Association 234 (3): 306-7.
28. Consroe, P.; Laguna, J.; Allender, J.; et al. 1991. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacology, Biochemistry and Behavior 40:701-8.
29. Cunha, J.M.; Carlini, E.A.; Pereira, A.E.; Ramos, O.L.; Pimentel, C.; Gagliardi, R.; Sanvito, W.L.; Lander, N. & Mechoulam, R. 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21 (3): 175-85.
30. Cunningham, D.; Bradley, C.; Forrest, G; et al. 1988. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. European Journal of Cancer and Clinical Oncology 24:685-9.
31. Cunningham, D.; Forrest, G.; Soukop, M.; Gilchrist, N. & Calder, I. 1985. Nabilone and prochlorperazine: A useful combination for emesis induced by cytotoxic drugs. British Medical Journal 29l:864-5.
32. Daaka, Y.; Friedman, H. & Klein, T.W. 1996. Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. Journal of Pharmacology and Experimental Therapeutics 276 (2): 776-83.
33. Derocq, J.M.; Segui, M.; Marchand, J.; Le Fur, G. & Casellas, P. 1995. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBSLellers 369 (2-3): 177-82.
34. Dickerson, S.J. 1980. Cannabis and its effect on anesthesia. Aana Journal 48 (6): 526-8.
35. Doblin, R. & Kleiman, M. 1991. Medical as anti-emetic medicine: A survey of oncologists' attitudes and experiences. Jourrnal of Clinical Oncology 9:1275-90.
36. Donald, P. 1986. Marijuana smoking—possible cause of head and neck carcinoma in young patients. Otolaryngology—Head and Neck Surgery 94 (4): 517-21.
37. Dunn, M. & Davis, R. 1974. The perceived effects of marijuana on spinal cord injured males. Paraplegia 12: 175.
38. Ellison, J.; Gelwan, E. & Ogletree, J. 1990. Complex partial seizure symptoms affected by marijuana abuse. Journal of Clinical Psychiatry 51 (10): 439-40.
39. El-Mallakh, R. 1987. Marijuana and migraine. Headache 27:442-3.
40. Eshhar, N.; Striem, S. & Biegon, A. 1993. HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5 (3): 237-40.
41. Facci, L.; Dal Toso, R.; Romanello, S.; Buriani, A.; Skaper, S.D. & Leon, A. 1995. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences of the United States of America 92 (8): 3376-80.
42. Feeney, D.M. 1978. Marihuana andepilepsy: Paradoxical anticonvulsant and convulsant effects. Advances in Bioscience 22-23:643-57.
43. Fried, P; Watkinson, B. & Willan, A. 1984. Marijuana use during pregnancy and decreased length of gestation. American Journal of Obstetrics and Gynecology 150:23-7.
44. Frytak, S.; Moertel, C.; O’Fallon, J.; et al. 1979. Delta-9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. Annals of Internal Medicine 91:825-30.
45. Greenberg, H; Werness, S; Pugh, J; et al. 1994. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clinical Pharmacology and Therapeutics 55:324-8.
46. Gregg, J.M.; Campbell, R.L.; Levin, K.J.; Ghia, J. & Elliott, R.A. 1976. Cardiovascular effects of cannabinol during oral surgery. Anesthesia and Analgesia 55 (2): 203-13.
47. Grinspoon, L. & Bakalar, J. 1995. Marijuana as medicine: A plea for reconsideration. Journal of the American Medical Association 273 (23): 1875-6.
48. Gruber, A. & Pope, H. 1994. Cannabis psychotic disorder: Does it exist? American Journal of Addiction 3:72-83.
49. Halikas, J.A.; Goodwin, D.W. & Guze, SB. 1972. Marihuana use and psychiatric illness. Archives of General Psychiatry 27 (2): 162-5.
50. Hammer, T. & Vaglum, P. 1990. Initiation, continuation or discontinuation of cannabis use the in general population. British Journal of Addiction 85:899-909.
51. Hohmann, A.G.; Martin, W.J.; Tsou, K. & Walker, J.M. 1995. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sciences 56 (2324): 2111-8.
52. Howlett, AC. 1995. Pharmacology of cannabinoid receptors. Annual Revue of Pharmacology and Toxicology 35:607-34. [Another good overview of newer cannabinoids and the cannibinoid receptors.]
53. Huber, G.; First, M. & Grubner, O. 1991. Marijuana and tobacco smoke gas-phase cytotoxins. Pharmacology, Biochemistry and Behavior 40:629-36.
54. Kabalik, J.; Krejci, Z. & Santany, F. 1960. Hemp as a medicament. Bulletin on Narcotics 12:5-19.
55. Kalofoutis, A.; Lekakis, J. & Koutselinis, A. 1980. Effects of delta 9-THC on human platelet phospholipids. Pharmacology, Biochemistry and Behavior 12 (5): 697-9.
56. Kaminski, N.E. 1993. Evidence for a cannabinoid receptor in immunomodulation by cannabinoid compounds. Advances in Experimental Medicine and Biology 335:115-20.
57. Kaslow, R.; Blackwelder, W.; Ostrow, D.; et al. 1989. No evidence for a role of alcohol or other psychoactive drugs in accelerating innumodeficiency in HIV-1 positive individuals. Journal of the American Medical Association 261 (23): 3424-9.
58. Kotin, J.; Post, R. & Goodwin, F. 1973. Tetrahydrocannabinol in depressed patients. Archives of General Psychiatry 28:345-8.
59. Landfield, P.W. & Eldridge, J.C. 1993. Neurotoxicity and drugs of abuse: Cannabinoid interaction with brain glucocorticoid receptors. In: NIDA Research Monograph No. 136:242-57.
60. Lewis, I.; Campbell, D. & Barrowcliffe, M. 1994. Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. British JournalofAnaesthesia 73:244-6.
61. Liskow, B. & Parker C. 1971. Allergy to marijuana. Annals of Internal Medicine 75:571-3.
62. Llamas, R.; Hart, R. & Schneider, N. 1978. Allergic bronchopulmonary aspergillosis associated with smoking moldy marijuana. Chest 6:8712.
63. Macnab, A.; Anderson, E. & Susak, L. 1989. Ingestion of cannabis: A cause of coma in children. Pediatric Emergency Care 5:238-9.
64. Mathers, D.; Ghodse, A.; Caan, A. & Scott, S. Cannabis use in a large sample of acute psychiatric admissions. British Journal of Addiction 86:779-84.
65. McCabe, M.; Smith, F.; Macdonald, J.; Woolley, P.; Goldberg, D. & Schein, P. 1988. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Investigational New Drugs 6:243-6.
66. Meinck, H.; Schonle, P. & Conrad B. 1989. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. Journal of Neurology 236:120-2.
67. Mikuriya, T. 1973. Marijuana: Medical Papers. Oakland, California: Medi-Comp Press.
68. Munson, A.E.; Harris, L.S.; Friedman, M.A.; Dewey, W.L. & Carchman, R.A. 1975. Antineoplastic activity of cannabinoids. Journal of the National Cancer Institute 55 (3): 597-602.
69. Musty, R.E.; Reggio, P. & Consroe, P. 1995. A review of recent advances in cannabinoid research and the 1994 International Symposium on Cannabis and the Cannabinoids. Life Sciences 56 (23-24): 1933-40.
70. Pate, D.W.; Jarvinen, K.; Urtti, A.; Jarho, P. & Jarvinen, T. 1995. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Current Eye Research 14 (9): 791-7.
71. Pettit, D.A.; Anders, D.L.; Harrison, M.P. & Cabral, G.A. 1996. Cannabinoid receptor expression in immune cells. Advances in Experimental Medicine and Biology 402:119-29.
72. Phuong, B. & Hart, L. 1993. DIAS Rounds: Dronabinol in tremor. Annals of Pharmacotherapy 27:1357-8.
73. Plasse, T.; Gorter, R.; Krasnow, S.; et al. 1991. Recent clinical experience with dronabinol. Pharmacology, Biochemistry and Behavior 40:695-700.
74. Polen, M.; Sidney, S.; Tekawa, I.; Sadler, M. & Freidman, G. 1993. Health care use by frequent marijuana smokers who do not smoke tobacco. Western Journal of Medicine 158:596-601.
75. Pope, H.; Gruber, A. & Yurgelun-Todd, D. 1995. The residual neuropsychological effects of cannabis: The current status of research. Drug and Alcohol Dependence. 38:25-34. [Excellent overview of issues and literature.]
76. Priestman, S.; Priestman, T. & Canney, P. 1987. A double-blind randomized cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea. Clinical Radiology 38:543-4.
77. Regelson, W.; Butler, J.R.; Schulz, J.; Kirk, T.; Peek, L.; Green, M.L. & Zalis, M.O. 1976. Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: M.C. Braude & S. Szara (Eds.) Pharmacology of Marihuana. Vol 2. New York: Raven Press.
78. Ries, R.K. 1993. The dually diagnosed patient with psychotic symptoms. Journal of Addictive Diseases 12 (3): 103-22.
79. Romero, J.; Garcia-Palomero, E.; Lin, S.Y.; Ramos, J.A.; Makriyannis, A. & Fernandez-Ruiz, J.J. 1996. Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB I receptor ligand. Life Sciences 58 (15): 1249-57.
80. Romero, J.; Garcia, L.; Cebeira, M.; Zadrozny, D.; Fernandez-Ruiz, J.J. & Ramos, J.A. 1995. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: Role of nigrostriatal dopaminergic neurons. Life Sciences 56 (23-24): 2033-40.
81. Rubio, F.; Quintero, S.; Hernandez, A.; et al. 1993. Flumazenil for coma reversal in children after cannabis. The Lancet 341:1028-9.
82. Sandyk, R. & Awerbuch, G. 1988. Marijuana and Tourette's syndrome. Journal of Clinical Psychopharmacology 8:444-5.
83. Schuel, H.; Goldstein, E.; Mechoulam, R.; Zimmerman, A.M. & Zimmerman, S. 1994. Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proceedings of the National Academy of Sciences of the United States of America 91 (16): 7678-82.
84. Schwartz, R. 1987. Marijuana: An overview. Pediatric Clinics of North America 34 (2): 305-17.
85. Sharma, T.D. 1972. Clinical observations of patients who used tetra-hydro cannabinol (T.H.C.) intravenously. Behavioral Neuropsychiatry 4 (7-8): 17-9.
86. Shohami, E.; Novikov, M. & Bass, R. 1995. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Research 674 (1): 55-62.
87. Sidney, S.; Beck, J.; Tekawa, I.; Quesenberry, C. & Friedman, G. 1997. Marijuana use and mortality. American Journal of Public Health 87:585-90.
88. Sifaneck, S. & Kaplan, C. 1995. Keeping off, stepping on and stepping off: The steppingstone theory reevaluated in the context of the Dutch cannabis experience. Contemporary Drug Problems 22 (Fall): 483-512.
89. Simmons, M. & Tashkin, D. 1995. The relationship of tobacco and marijuana smoking characteristics. Life Sciences 56:2185-91.
90. Simpson, H. 1986. Epidemiology of road accidents involving marijuana. Alcohol, Drugs, Driving 2: 15-30.
91. Skaper, S.D.; Buriani, A.; Dal Toso, R.; et al. 1996. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proceedings of the National Academy of Sciences of the United States of America 93 (9): 3984-9.
92. Smith, M.S.; Yamamoto, Y.; Newton, C.; Friedman, H. & Klein, T. 1997. Psychoactive cannabinoids increase mortality and alter acute phase cytokine responses in mice sublethally infected with Legionella pneumophila. Proceedings of the Society for Experimental Biology and Medicine 214 (I): 69-75.
93. Soueif, M. I. 1975. Chronic cannabis users: Further analysis of objective test results. Bulletin on Narcotics 27 (4): 1-26.
94. Sugrue, M.; Seger, M.; Dredge, G.; et al. 1995. Evaluation of the prevalence of drug and alcohol abuse in motor vehicle trauma in south western Sydney. Australian and New Zealand Journal of Surgery 65 (12): 853-6.
95. Tashkin, D.; Calvarese, B.; Simmons, M. & Shapiro, B. 1980. Respiratory status of seventy-four habitual marijuana smokers. Chest 78:699-706.
96. Tashkin, D.; Simmons, M.; Chang, P.; Liu, H. & Coulson, A. 1993. Effects of smoked substance abuse on nonspecific airway hyperresponsiveness. American Review of Respiratory Disease 147:97-103.
97. Tashkin, D.; Coulson, A.; Clark, V.; et al. 1987. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. American Review of Respiratory Disease 135:209-16.
98. Tashkin, D.; Reiss, S.; Shapiro, B.; Calvarese, B.; Olsen, J. & Lodge, J. 1977. Bronchial effects ofaerosolized delta-9-tetrahydrocannabinol in healthy and asthmatic subjects. American Review of Respiratory Disease 115:57-65.
99. Tashkin, D.; Soares, J. & Helpler, R; et al. 1978. Cannabis. 1977. Annals of Internal Medicine 89:539-49.
100. Taylor, D.N.; Wachsmuth, I.K.; Shangkuan, Y.H.; Schmidt, E.V.; Barrett, T.J.; Schrader, J.S.; Scherach, C.S.; McGee, H.B.; Feldman, R.A. & Brenner, D.J. 1982. Salmonellosis associated with marijuana: A multistate outbreak traced by plasmid fingerprinting. New England Journal of Medicine 306 (21): 1249-53.
101. Thomas, H. 1996. A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence 42:201-7.
102. Tilles, D.S.; Goldenheim, P.D.; Johnson, D.C.; Mendelson, J.H.; Mello, N.K. & Hales, C.A. 1986. Marijuana smoking as cause of reduction in single-breath carbon monoxide diffusing capacity. American Journal of Medicine 80 (4): 601-6.
103. Tortorice, P. & O'Connell, M. 1990. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10 (2): 129-145.
104. Tsou, K.; Patrick, S.L. & Walker, J.M. 1995. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. European Journal of Pharmacology 280 (3): R13-5.
105. Vela, G.; Ruiz-Gayo, M. & Fuentes, J.A. 1995. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34 (6): 665-8.
106. Vered, M.; Bar-Joseph, A.; Belayev, L.; Berkovich, Y. & Biegon, A. 1994. Anti-ischemia activity of HU-211, a non-psychotropic synthetic cannabinoid. Acta Neurochirurgica Supplementum (Wien) 60:3357.
107. Vieweg, W. & Hillard J. 1987. Adverse interactions of cannabis with psychotropic medicines. Psychiatric Medicine 4 (1): 69-77. [Excellent review of overall drug effects of cannabinoids.]
108. Voth, E. & Schwartz, R. 1997. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Annals of Intetrnal Medicine 126:791-8.
109. Williams, J.; Wellman, N. & Rawlins, J. 1996. Cannabis use correlates with schizotypy in healthy people. Addiction 91 (6): 869-77.
110. Williams, S.; Hartley, J. & Graham, J. 1976. Bronchodilator effect of delta-1 -tetrahydrocannabinol administered by aerosol to asthmatic patients. Thorax 31:720-3.
111. Wirguin, I.; Mechoulam, R.; Breuer, A.; Schezen, E.; Weidenfeld, J. & Brenner, T. 1994. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. lmmunopharmacology 28 (3): 209-14.
112. Zhu, W.; Igarashi, T.; Friedman, H. & Klein, T.W. 1995. Delta 9-Tetrahydrocannabinol (THC) causes the variable expression of 112 receptor subunits. Journal of Pharmacology and Experimental Therapeutics 274 (2): 1001-7.
113. Zuardi, A.; Shirakawa, I.; Finkelfarb, E. & Karniol, I. 1982. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology 76:245-50.
114. Zuckerman, B.; Frank, D.; Hingson, R.; et al. 1989. Effects of maternal marijuana and cocaine use on fetal growth. New England Journal of Medicine 320 (12): 762-68.